(Q53355927)

13 May 2018

title

CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients. (English)

1 reference

13 May 2018

author

Burkhardt Seifert

5

1 reference

13 May 2018

author name string

Andreas Trojan

1

1 reference

13 May 2018

Athanasios Vergopoulos

2

1 reference

13 May 2018

Urs Breitenstein

3

1 reference

13 May 2018

Christoph Tausch

4

1 reference

13 May 2018

Wolfgang Joechle

6

1 reference

13 May 2018

publication date

26 October 2012

1 reference

13 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

13 May 2018

volume

71

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

page(s)

301-306

1 reference

13 May 2018

Genotype-guided tamoxifen therapy: time to pause for reflection?

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Pharmacogenetics of endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patien

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Pharmacogenomics of tamoxifen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Ontogeny of dextromethorphan O- and N-demethylation in the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Initialization of adjuvant hormonal treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2003-Y

10.1007/S00280-012-2003-Y

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018